Received 14 July 2005/Accepted 3 September 2005
|
|
- Oscar Martin Henry
- 5 years ago
- Views:
Transcription
1 JOURNAL OF VIROLOGY, Dec. 2005, p Vol. 79, No X/05/$ doi: /jvi Copyright 2005, American Society for Microbiology. All Rights Reserved. Tat SL8-Specific CD8 T Lymphocytes Are More Effective than Gag CM9-Specific CD8 T Lymphocytes at Suppressing Simian Immunodeficiency Virus Replication in a Functional In Vitro Assay John T. Loffredo, 1 Eva G. Rakasz, 1 Juan Pablo Giraldo, 2 Sean P. Spencer, 2 Kelly K. Grafton, 1 Sarah R. Martin, 2 Gnankang Napoé, 1 Levi J. Yant, 2 Nancy A. Wilson, 1 and David I. Watkins 1,2 * Wisconsin National Primate Research Center 1 and Department of Pathology and Laboratory Medicine, 2 University of Wisconsin, Madison, Wisconsin Received 14 July 2005/Accepted 3 September 2005 Epitope-specific CD8 T lymphocytes may play an important role in controlling human immunodeficiency virus (HIV)/simian immunodeficiency virus replication. Unfortunately, standard cellular assays do not measure the antiviral efficacy (the ability to suppress virus replication) of CD8 T lymphocytes. Certain epitopespecific CD8 T lymphocytes may be better than others at suppressing viral replication. We compared the antiviral efficacy of two immunodominant CD8 T lymphocyte responses Tat SL8 and Gag CM9 by using a functional in vitro assay. Viral suppression by Tat-specific CD8 T lymphocytes was consistently greater than that of Gag-specific CD8 T lymphocytes. Such differences in antigen-specific CD8 -T-lymphocyte efficacy may be important for selecting CD8 T lymphocyte epitopes for inclusion in future HIV vaccines. Several lines of evidence suggest that CD8 T lymphocytes are important in suppressing human immunodeficiency virus/ simian immunodeficiency virus (HIV/SIV) replication. The appearance of HIV-specific CD8 T lymphocytes is correlated temporally with a precipitous reduction in viral load (8, 20) implying that these virus-specific effector cells control viral replication. However, the massive loss of memory CD4 T cells during acute HIV/SIV infection also likely contributes to the initial reduction in viral replication (21, 26). Additional evidence implicating CD8 T cells in the control of viral replication comes from the depletion of circulating CD8 lymphocytes in SIV-infected macaques, which results in an increase in plasma viral concentrations (16, 24, 35). In addition, CD8 -T-lymphocytes exert selective pressure on viral sequences in vivo, selecting for immune escape variants in both the acute (3, 9, 30) and the chronic (6, 7, 10, 11, 14, 32) phase of HIV/SIV infection. Over the past decade, new methodologies have improved our ability to detect CD8 -T-lymphocyte responses against HIV/SIV. However, we still do not know which of these HIVspecific CD8 T lymphocytes actually contributes to control of viral replication. While neutralization assays distinguish effective antibodies from ineffective ones, most current cellular assays rely on indirect readouts to measure CD8 -T-lymphocyte efficacy (44). Early studies demonstrated that CD8 cells (38) and later virus-specific cytotoxic T lymphocytes (45) inhibited immunodeficiency virus replication in vitro. Recently, investigators using functional in vitro assays suggested that * Corresponding author. Mailing address: Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, 585 Science Dr., Madison, WI Phone: (608) Fax: (608) watkins@primate.wisc.edu. CD8 -T-lymphocyte clones directed against early-expressed viral proteins, Nef (1, 46) and Rev (39, 40), may be particularly effective in suppressing viral replication. Another study demonstrated effective viral suppression using Pol-specific CD8 T lymphocytes (37). Furthermore, dendritic cells pulsed with inactivated autologous virus can expand virus-specific CD8 T cells, which are then capable of controlling HIV replication (23). While most data suggest that there are differences among the various CD8 -T-lymphocyte populations in their antiviral efficacy (the ability to suppress virus replication), current studies are limited by relying on a small number of well-defined clones. Moreover, the attributes of an effective CD8 -T-lymphocyte response are still undefined. Development of the viral suppression assay (VSA). To better address questions of antiviral efficacy, we developed a functional in vitro viral suppression assay to assess the ability of CD8 T lymphocytes to control SIV replication. We depleted uninfected Indian rhesus macaque (Macaca mulatta) PBMC of CD8 cells using CD8 nonhuman primate microbeads on an AutoMACS bead separation unit (Miltenyi, Auburn, CA) according to the manufacturer s protocol. Depletions were 99% effective (Fig. 1A). We stimulated the CD8 fraction with 5 g/ml of phytohemagglutinin (Sigma, St. Louis, MO) for 18 to 24 h. The CD8 targets were then incubated with SIV mac 239 (17) at a multiplicity of infection of for 4 h. This multiplicity of infection reproducibly infected the CD8 peripheral blood mononuclear cells (PBMC) target cells and provided exponential SIV replication during the initial days of the assay. We used in vitro-stimulated epitope-specific CD8 -T-cell lines as effector cells. Cell lines were generated from fresh or CD8-enriched PBMC from SIV mac 239-infected Mamu-A*
2 VOL. 79, 2005 NOTES Downloaded from FIG. 1. VSA schematic. (A) Target cells are freshly isolated PBMC, depleted of CD8 cells, and activated with phytohemagglutinin (PHA). (B) Effector cells are SIV-specific in vitro-stimulated CD8 T cells that are sorted to high specificity. (C) After a 4-h incubation of the target cells with SIV mac 239, we combined target and effector cells at E:T ratios of 1:10, and 1:20. The cocultures were maintained for 8 to 11 days. 0.5 ml of supernatant was taken every 2 days for vrna quantification. MOI, multiplicity of infection. on September 21, 2018 by guest macaques in the chronic phase by using previously described methods (42). Intracellular cytokine staining assays verified that the in vitro cultures produced gamma interferon and tumor necrosis factor alpha in response to their cognate antigen and were not functionally impaired as has been observed in vivo (5, 13, 41). We performed Mamu-A*01 tetramer stains (2) to measure epitope specificity. Typically, after 1 to 3 months, CD8 -T-cell lines reached a suitable specificity ( 50%) for cell sorting. We sorted CD3, CD8, and Mamu-A*01 tetramer lymphocytes using a MoFlo cell sorter (DakoCytomation, Fort Collins, CO). Post-sort analysis was performed to assess purity (typically 99%) and viability as assessed by trypan blue exclusion (Gibco, Grand Island, NY) (Fig. 1B). In cases where a cell line was 94% tetramer-positive CD8 T lymphocytes but in limited quantities, we used unsorted cells after verifying that other immunodominant CD8 -T-lymphocyte responses were absent. We added infected CD8 lymphocytes (targets) to each well of a 24-well plate (Fig. 1C). Sorted CD8 T cells (effectors) were added to wells at effector to target ratios (E:T) of 1:10 and 1:20. We chose these E:Ts because early testing indicated E:Ts above 1:10 would sometimes provide viral sup-
3 14988 NOTES J. VIROL. FIG. 2. Day 8 intracellular Gag p27 staining of representative VSA results with Tat SL8- and Gag CM9-specific CD8 T-lymphocytes from a single macaque (animal 2125). Results for MHC class I-matched effector and target cells (A) and MHC-mismatched effector (Mamu- A*01 ) and target (Mamu-A*01 ) cells (B) at an E:T of 1:10 are shown. Viral suppression only occurred in an MHC class I-restricted fashion. pression in our major histocompatibility complex (MHC)-mismatched controls, whereas ratios below 1:20 would not provide consistent levels of viral suppression. The final volume of cell culture medium was 2 ml and contained 50 U of interleukin-2 (NIH AIDS Research and Reference Reagent Program, Germantown, MD)/ml. The cocultures were maintained for 8 to 11 days. Every 2 days, 0.5 ml of supernatant was collected and replaced with fresh medium. We purified vrna from 400 lof supernatant using the MagAttract vrna minikit on a BioRobot M48 workstation (QIAGEN, Valencia, CA). Viral loads were determined by quantitative reverse transcription-pcr on a LightCycler 2.0 (Roche Diagnostics, Indianapolis, IN) as
4 VOL. 79, 2005 NOTES FIG. 3. Quantitative PCR of representative VSA results with Tat SL8- and Gag CM9-specific CD8 T lymphocytes from macaque Results for MHC class I-matched effector and target cells (A) MHC-mismatched effector (Mamu-A*01 ) and target (Mamu-A*01 ) cells (B) at an E:T of 1:10 are shown. Viral suppression only occurred in an MHC class I-restricted fashion. previously described (27). At the end of a VSA, intracellular Gag p27 staining was performed on the coculture to measure SIV mac 239 infection. We first stained for the cell surface markers CD3, CD4, and CD8, followed by intracellular Gag p27 staining using Fix and Perm (CALTAG, Burlingame, CA) according to the manufacturer s protocol with fluorescently conjugated 55-2F12 Gag p27 antibody (NIH AIDS Research and Reference Reagent Program, Germantown, MD) at 0.75 mg/ ml. Differences in the antiviral efficacy of Tat SL8- and Gag CM9-specific CD8 T lymphocytes. Tat SL8 and Gag CM9 are Mamu-A*01-restricted immunodominant epitopes (6, 29, 31) often studied in macaque vaccine experiments (4, 6, 7, 15, 36, 43). These two responses account for 50% of the total SIV-specific CD8 responses in Mamu- A*01 macaques (29). Despite extensive studies, the antiviral efficacies of these two high frequency CD8 -T-lymphocyte responses have not been addressed. We used the VSA to compare the ability of Tat SL8- and Gag CM9-specific CD8 T lymphocytes to suppress SIV mac 239 replication. Both cellular responses diminished viral replication at E:Ts of 1:10 and 1:20 as determined by intracellular Gag p27 staining (Fig. 2A) and quantitative reverse transcription-pcr (Fig. 3A) compared to wells containing only target cells. To ensure viral suppression was MHC class I-restricted, we combined Mamu-A*01 target cells with Mamu-A*01-restricted effectors FIG. 4. Day 8 viral suppression by Tat SL8- and Gag CM9- specific CD8 T lymphocytes derived from several SIV-infected macaques (animal identification number shown below bars) at an E:T ratio of 1:10 as measured by fold reduction of intracellular Gag p27 (A) and fold reduction of vrna copies/ml (B). Bars:, Tat-specific cells;, Gag-specific cells. as controls in each assay. Using MHC-mismatched effector and target cells, we observed negligible reduction in SIV replication compared to wells that contain targets only in the absence of effective CD8 T cells (Fig. 2B and 3B). At E:Ts of 1:10 and 1:20, the Tat SL8-specific CD8 T lymphocytes suppressed viral replication better than CD8 T lymphocytes against Gag CM9 did. By day 8, at an E:T of 1:10, the Tat SL8-specific CD8 T lymphocytes effectively suppressed viral replication, reducing the number of Gag p27- positive cells to below background (Fig. 2A). Viral RNA concentrations in these wells were 240-fold lower than control wells (Fig. 3A). These results were consistent in at least two independent assays with CD8 -T-cell lines derived from the same animal (data not shown). Next, we examined whether suppression was animal- and/or epitope-specific using CD8 -T-cell lines generated from several Mamu-A*01 SIV-infected macaques. In all instances, Tat-specific CD8 T lymphocytes suppressed viral replication more than Gag-specific CD8 T lymphocytes did (Fig. 4). Although animal 2095 had the least effective Tat SL8-specific CD8 T lymphocytes, there was still a 10-fold decrease in intracellular Gag p27 staining and a 47-fold decrease in viral
5 14990 NOTES J. VIROL. RNA concentration on day 8 relative to wells without effector cells (Fig. 4). Our results displayed similar trends over time in multiple independent assays (data not shown). While Tat-specific CD8 T lymphocytes cells were more effective in their ability to suppress SIV replication, we observed some animal-to-animal variability (Fig. 4). This variability may reflect differences in the immunological and virological status of animals at the time of cell line generation. For instance, studies correlate the impairment of CD8 -T-cell function and proliferative capacity with the loss of CD4 T cells (22, 25, 28). Animal 2095 had low CD4 counts ( 200 cells/ l) when PBMC were obtained to generate the Tat SL8-specific CD8 -T-cell line. Interestingly, this animal produced the least effective Tat-specific cell line (Fig. 4). While epitope-specific CD8 T-lymphocytes can inhibit viral replication by cytolytic and noncytolytic mechanisms, the reduction in SIV replication by our epitope-specific CD8 T lymphocytes is likely occurring by cytolytic activity in a MHC class I-restricted fashion. Previous findings demonstrated that epitope-specific CD8 -T-lymphocytes suppressed viral replication primarily through direct cytolytic activity (12, 45). Although it appears that noncytolytic effects may play a role, it is likely minor and contingent on direct cell-to-cell interactions via MHC-TCR recognition. Although these studies demonstrated that soluble factors inhibit HIV/SIV replication in a MHC class I-unrestricted fashion (12, 45), we observed minimal, if any, viral suppression when the effector and target cells were MHC mismatched (Fig. 2B and 3B). Nevertheless, we cannot rule out the involvement of noncytolytic activity in our assay. When performing fluorescence-activated cell sorting analysis at the end of the assay, we found that the percentages of effector cells directed against Tat SL8 and Gag CM9 in the cocultures were comparable in most cases. There were some instances in which Gag CM9-specific CD8 T lymphocytes persisted in two- to fourfold greater numbers than those against Tat SL8. However, even in these cases, the greater abundance of Gag CM9-specific CD8 T lymphocytes did not suppress of SIV mac 239 replication as well as Tat SL8-specific CD8 T lymphocytes. This suggests that a difference in antiviral efficacy is not simply due to lymphocyte longevity. Previous studies have failed to address the antiviral efficacy of Tat SL8- and Gag CM9-specific CD8 T-lymphocytes, although they have suggested possible reasons for the observed efficacy of the Tat-specific CD8 T cells. Tat-specific mrna is detected as early as 4 h after HIV infection, whereas Gag-specific mrna appears approximately 20 h postinfection (18, 19, 33, 34). In addition, Tat SL8-specific cells appear to have a higher functional avidity ( 0.18 nm) compared to that of the Gag CM9-specific cells ( 13.3 nm) (30). These differences might enable the Tat-specific CD8 T cells to recognize cells early in the virus replication cycle and those that present only small amounts of antigen. Our viral suppression assay measures the ability of antigenspecific CD8 T lymphocytes to suppress SIV replication in vitro. We used this assay to show that Tat SL8-specific CD8 T lymphocytes are consistently more effective at suppressing SIV mac 239 replication than Gag CM9-specific CD8 T lymphocytes. Using this assay, we hope to define additional potentially protective CD8 -T-lymphocyte responses. It is plausible that findings from our functional in vitro assay can be extrapolated to the ability to suppress HIV/SIV replication in vivo. Therefore, differences in CD8 -T-lymphocyte suppressive efficacy may be critically important when choosing epitopes for future HIV vaccines. We thank William Rehrauer, Jess Maxwell, and Tim Jacoby for MHC class I PCR-SSP typing and gratefully acknowledge Laura Valentine, Alex Ko, and Andrea Weiler for immunological assay assistance. David O Connor and Thomas Friedrich provided helpful discussions. We also thank the Immunology and Virology Core Laboratories at the National Primate Research Center, University of Wisconsin-Madison for technical assistance. This research was supported by National Institutes of Health grants R01 AI to D.I.W. and P51 RR to the Wisconsin National Primate Research Center (WNPRC). This study was conducted in part at a facility constructed with support from Research Facilities Improvement grant numbers RR and RR (WNPRC). REFERENCES 1. Ali, A., R. Lubong, H. Ng, D. G. Brooks, J. A. Zack, and O. O. Yang Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J. Virol. 78: Allen, T. M., B. R. Mothe, J. Sidney, P. Jing, J. L. Dzuris, M. E. Liebl, T. U. Vogel, D. H. O Connor, X. Wang, M. C. Wussow, J. A. Thomson, J. D. Altman, D. I. Watkins, and A. Sette CD8 lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-a*01: implications for vaccine design and testing. J. Virol. 75: Allen, T. M., D. H. O Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, K. J. Kunstman, X. Wang, D. B. Allison, A. L. Hughes, R. C. Desrosiers, J. D. Altman, S. M. Wolinsky, A. Sette, and D. I. Watkins Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407: Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292: Appay, V., D. F. Nixon, S. M. Donahoe, G. M. Gillespie, T. Dong, A. King, G. S. Ogg, H. M. Spiegel, C. Conlon, C. A. Spina, D. V. Havlir, D. D. Richman, A. Waters, P. Easterbrook, A. J. McMichael, and S. L. Rowland- Jones HIV-specific CD8 T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192: Barouch, D. H., J. Kunstman, J. Glowczwskie, K. J. Kunstman, M. A. Egan, F. W. Peyerl, S. Santra, M. J. Kuroda, J. E. Schmitz, K. Beaudry, G. R. Krivulka, M. A. Lifton, D. A. Gorgone, S. M. Wolinsky, and N. L. Letvin Viral escape from dominant simian immunodeficiency virus epitopespecific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J. Virol. 77: Barouch, D. H., J. Kunstman, M. J. Kuroda, J. E. Schmitz, S. Santra, F. W. Peyerl, G. R. Krivulka, K. Beaudry, M. A. Lifton, D. A. Gorgone, D. C. Montefiori, M. G. Lewis, S. M. Wolinsky, and N. L. Letvin Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415: Borrow, P., H. Lewicki, B. H. Hahn, G. M. Shaw, and M. B. Oldstone Virus-specific CD8 cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68: Borrow, P., H. Lewicki, X. Wei, M. S. Horwitz, N. Peffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. H. Hahn, M. B. Oldstone, and G. M. Shaw Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3: Chen, Z. W., A. Craiu, L. Shen, M. J. Kuroda, U. C. Iroku, D. I. Watkins, G. Voss, and N. L. Letvin Simian immunodeficiency virus evades a dominant epitope-specific cytotoxic T lymphocyte response through a mutation resulting in the accelerated dissociation of viral peptide and MHC class I. J. Immunol. 164: Evans, D. T., D. H. O Connor, P. Jing, J. L. Dzuris, J. Sidney, J. da Silva, T. M. Allen, H. Horton, J. E. Venham, R. A. Rudersdorf, T. Vogel, C. D. Pauza, R. E. Bontrop, R. DeMars, A. Sette, A. L. Hughes, and D. I. Watkins Virus-specific cytotoxic T-lymphocyte responses select for amino-acid
6 VOL. 79, 2005 NOTES variation in simian immunodeficiency virus Env and Nef. Nat. Med. 5: Gauduin, M. C., R. L. Glickman, R. Means, and R. P. Johnson Inhibition of simian immunodeficiency virus (SIV) replication by CD8 T lymphocytes from macaques immunized with live attenuated SIV. J. Virol. 72: Goepfert, P. A., A. Bansal, B. H. Edwards, G. D. Ritter, Jr., I. Tellez, S. A. McPherson, S. Sabbaj, and M. J. Mulligan A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J. Virol. 74: Goulder, P. J., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, A. J. McMichael, and S. Rowland-Jones Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3: Horton, H., T. U. Vogel, D. K. Carter, K. Vielhuber, D. H. Fuller, T. Shipley, J. T. Fuller, K. J. Kunstman, G. Sutter, D. C. Montefiori, V. Erfle, R. C. Desrosiers, N. Wilson, L. J. Picker, S. M. Wolinsky, C. Wang, D. B. Allison, and D. I. Watkins Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76: Jin, X., D. E. Bauer, S. E. Tuttleton, S. Lewin, A. Gettie, J. Blanchard, C. E. Irwin, J. T. Safrit, J. Mittler, L. Weinberger, L. G. Kostrikis, L. Zhang, A. S. Perelson, and D. D. Ho Dramatic rise in plasma viremia after CD8 T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189: Kestler, H., T. Kodama, D. Ringler, M. Marthas, N. Pedersen, A. Lackner, D. Regier, P. Sehgal, M. Daniel, N. King, et al Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248: Kim, S. Y., R. Byrn, J. Groopman, and D. Baltimore Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J. Virol. 63: Klotman, M. E., S. Kim, A. Buchbinder, A. DeRossi, D. Baltimore, and F. Wong-Staal Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc. Natl. Acad. Sci. USA 88: Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68: Li, Q., L. Duan, J. D. Estes, Z. M. Ma, T. Rourke, Y. Wang, C. Reilly, J. Carlis, C. J. Miller, and A. T. Haase Peak SIV replication in resting memory CD4 T cells depletes gut lamina propria CD4 T cells. Nature 434: Lichterfeld, M., D. E. Kaufmann, X. G. Yu, S. K. Mui, M. M. Addo, M. N. Johnston, D. Cohen, G. K. Robbins, E. Pae, G. Alter, A. Wurcel, D. Stone, E. S. Rosenberg, B. D. Walker, and M. Altfeld Loss of HIV-1-specific CD8 T-cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4 T cells. J. Exp. Med. 200: Lu, W., and J. M. Andrieu In vitro human immunodeficiency virus eradication by autologous CD8 T cells expanded with inactivated-viruspulsed dendritic cells. J. Virol. 75: Matano, T., R. Shibata, C. Siemon, M. Connors, H. C. Lane, and M. A. Martin Administration of an anti-cd8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72: Matloubian, M., R. J. Concepcion, and R. Ahmed CD4 T cells are required to sustain CD8 cytotoxic T-cell responses during chronic viral infection. J. Virol. 68: Mattapallil, J. J., D. C. Douek, B. Hill, Y. Nishimura, M. Martin, and M. Roederer Massive infection and loss of memory CD4 T cells in multiple tissues during acute SIV infection. Nature 434: McDermott, A. B., J. Mitchen, S. Piaskowski, I. De Souza, L. J. Yant, J. Stephany, J. Furlott, and D. I. Watkins Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J. Virol. 78: Migueles, S. A., A. C. Laborico, W. L. Shupert, M. S. Sabbaghian, R. Rabin, C. W. Hallahan, D. Van Baarle, S. Kostense, F. Miedema, M. McLaughlin, L. Ehler, J. Metcalf, S. Liu, and M. Connors HIV-specific CD8 T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3: Mothe, B. R., H. Horton, D. K. Carter, T. M. Allen, M. E. Liebl, P. Skinner, T. U. Vogel, S. Fuenger, K. Vielhuber, W. Rehrauer, N. Wilson, G. Franchini, J. D. Altman, A. Haase, L. J. Picker, D. B. Allison, and D. I. Watkins Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J. Virol. 76: O Connor, D. H., T. M. Allen, T. U. Vogel, P. Jing, I. P. DeSouza, E. Dodds, E. J. Dunphy, C. Melsaether, B. Mothe, H. Yamamoto, H. Horton, N. Wilson, A. L. Hughes, and D. I. Watkins Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8: O Connor, D. H., B. R. Mothe, J. T. Weinfurter, S. Fuenger, W. M. Rehrauer, P. Jing, R. R. Rudersdorf, M. E. Liebl, K. Krebs, J. Vasquez, E. Dodds, J. Loffredo, S. Martin, A. B. McDermott, T. M. Allen, C. Wang, G. G. Doxiadis, D. C. Montefiori, A. Hughes, D. R. Burton, D. B. Allison, S. M. Wolinsky, R. Bontrop, L. J. Picker, and D. I. Watkins Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-t-lymphocyte responses. J. Virol. 77: Phillips, R. E., S. Rowland-Jones, D. F. Nixon, F. M. Gotch, J. P. Edwards, A. O. Ogunlesi, J. G. Elvin, J. A. Rothbard, C. R. Bangham, C. R. Rizza, and A. J. McMichael Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354: Pomerantz, R. J., D. Trono, M. B. Feinberg, and D. Baltimore Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell 61: Ranki, A., A. Lagerstedt, V. Ovod, E. Aavik, and K. J. Krohn Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat, and Rev in acutely and chronically infected lymphoid cell lines. Arch. Virol. 139: Schmitz, J. E., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, J. Ghrayeb, M. A. Forman, D. C. Montefiori, E. P. Rieber, N. L. Letvin, and K. A. Reimann Control of viremia in simian immunodeficiency virus infection by CD8 lymphocytes. Science 283: Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: Tomiyama, H., M. Fujiwara, S. Oka, and M. Takiguchi Cutting edge: epitope-dependent effect of Nef-mediated HLA class I down-regulation on ability of HIV-1-specific CTLs to suppress HIV-1 replication. J. Immunol. 174: Tsubota, H., C. I. Lord, D. I. Watkins, C. Morimoto, and N. L. Letvin A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J. Exp. Med. 169: van Baalen, C. A., C. Guillon, M. van Baalen, E. J. Verschuren, P. H. Boers, A. D. Osterhaus, and R. A. Gruters Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes. Eur. J. Immunol. 32: Van Baalen, C. A., M. Schutten, R. C. Huisman, P. H. Boers, R. A. Gruters, and A. D. Osterhaus Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J. Virol. 72: Vogel, T. U., T. M. Allen, J. D. Altman, and D. I. Watkins Functional impairment of simian immunodeficiency virus-specific CD8 T cells during the chronic phase of infection. J. Virol. 75: Vogel, T. U., T. C. Friedrich, D. H. O Connor, W. Rehrauer, E. J. Dodds, H. Hickman, W. Hildebrand, J. Sidney, A. Sette, A. Hughes, H. Horton, K. Vielhuber, R. Rudersdorf, I. P. De Souza, M. R. Reynolds, T. M. Allen, N. Wilson, and D. I. Watkins Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence? J. Virol. 76: Vogel, T. U., M. R. Reynolds, D. H. Fuller, K. Vielhuber, T. Shipley, J. T. Fuller, K. J. Kunstman, G. Sutter, M. L. Marthas, V. Erfle, S. M. Wolinsky, C. Wang, D. B. Allison, E. W. Rud, N. Wilson, D. Montefiori, J. D. Altman, and D. I. Watkins Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J. Virol. 77: Yang, O. O Will we be able to spot an effective HIV-1 vaccine? Trends Immunol. 24: Yang, O. O., S. A. Kalams, A. Trocha, H. Cao, A. Luster, R. P. Johnson, and B. D. Walker Suppression of human immunodeficiency virus type 1 replication by CD8 cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71: Yang, O. O., P. T. Sarkis, A. Trocha, S. A. Kalams, R. P. Johnson, and B. D. Walker Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. J. Immunol. 171:
Magnitude and Diversity of Cytotoxic-T-Lymphocyte Responses Elicited by Multiepitope DNA Vaccination in Rhesus Monkeys
JOURNAL OF VIROLOGY, Sept. 2003, p. 10113 10118 Vol. 77, No. 18 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.18.10113 10118.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Magnitude
More informationJVI Accepts, published online ahead of print on 7 March 2007 J. Virol. doi: /jvi
JVI Accepts, published online ahead of print on 7 March 2007 J. Virol. doi:10.1128/jvi.02763-06 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationReceived 16 February 2004/Accepted 5 June 2004
JOURNAL OF VIROLOGY, Oct. 2004, p. 11434 11438 Vol. 78, No. 20 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.20.11434 11438.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Heterologous
More informationEmergence and Kinetics of Simian Immunodeficiency Virus-Specific CD8 T Cells in the Intestines of Macaques during Primary Infection
JOURNAL OF VIROLOGY, Nov. 2001, p. 10515 10519 Vol. 75, No. 21 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.21.10515 10519.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Emergence
More informationAnti-SIV Cytolytic Molecules in Pigtail Macaques
AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 24, Number 8, 2008 Mary Ann Liebert, Inc. DOI: 10.1089/aid.2008.0081 Anti-SIV Cytolytic Molecules in Pigtail Macaques Erik Rollman, Stephen J. Turner, Katherine
More informationA DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques
Journal of General Virology (2002), 83, 75 80. Printed in Great Britain... SHORT COMMUNICATION A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses
More informationVaccine-Induced T Cells Control Reversion of AIDS Virus Immune Escape Mutants
JOURNAL OF VIROLOGY, Apr. 2007, p. 4137 4144 Vol. 81, No. 8 0022-538X/07/$08.00 0 doi:10.1128/jvi.02193-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Vaccine-Induced T Cells
More informationAnalysis of Total Human Immunodeficiency Virus (HIV)-Specific CD4 and CD8 T-Cell Responses: Relationship to Viral Load in Untreated HIV Infection
JOURNAL OF VIROLOGY, Dec. 2001, p. 11983 11991 Vol. 75, No. 24 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.24.11983 11991.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Analysis
More informationReceived 14 April 2005/Accepted 7 August 2005
JOURNAL OF VIROLOGY, Dec. 2005, p. 15547 15555 Vol. 79, No. 24 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.24.15547 15555.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Attenuation
More informationReceived May 1, 2002; returned to author for revision May 20, 2002; accepted June 3, 2002
Virology 301, 365 373 (2002) doi:10.1006/viro.2002.1598 A Simian Immunodeficiency Virus Nef Peptide Is a Dominant Cytotoxic T Lymphocyte Epitope in Indian-Origin Rhesus Monkeys Expressing the Common MHC
More informationIs an HIV Vaccine Possible?
304 BJID 2009; 13 (August) Is an HIV Vaccine Possible? Nancy A. Wilson 1,2 and David I. Watkins 1,2 1 Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; 2 Wisconsin National
More informationReceived 30 December 2006/Accepted 25 February 2007
JOURNAL OF VIROLOGY, May 2007, p. 5202 5211 Vol. 81, No. 10 0022-538X/07/$08.00 0 doi:10.1128/jvi.02881-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Long-Term Control of Simian
More informationComparative Efficacy of Subtype AE Simian-Human Immunodeficiency Virus Priming and Boosting Vaccines in Pigtail Macaques
JOURNAL OF VIROLOGY, Jan. 2007, p. 292 300 Vol. 81, No. 1 0022-538X/07/$08.00 0 doi:10.1128/jvi.01727-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparative Efficacy of
More informationRapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
More informationSupporting Information
Supporting Information Sui et al..7/pnas.997 Pre-CLP CM9 LA9 SL Tat# Pol Vif % Tetramer + CD + CD + Vac+IL- +IL- Vac Fig. S. Frequencies of six different CD + CD + Mamu-A*-tetramer + cells were measured
More informationReceived 19 September 2007/Accepted 21 November 2007
JOURNAL OF VIROLOGY, Feb. 2008, p. 1723 1738 Vol. 82, No. 4 0022-538X/08/$08.00 0 doi:10.1128/jvi.02084-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Patterns of CD8 Immunodominance
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationEmergence of cytotoxic T lymphocyte escape mutations in nonpathogenic simian immunodeficiency virus infection
Eur. J. Immunol. 2001. 31: 3207 3217 CTL escape in nonpathogenic SIV infection 3207 Emergence of cytotoxic T lymphocyte escape mutations in nonpathogenic simian immunodeficiency virus infection Amitinder
More informationFitness Costs Limit Viral Escape from Cytotoxic T Lymphocytes at a Structurally Constrained Epitope
JOURNAL OF VIROLOGY, Dec. 2004, p. 13901 13910 Vol. 78, No. 24 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.24.13901 13910.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Fitness
More informationReceived 2 August 2002/Accepted 13 August 2002
JOURNAL OF VIROLOGY, Nov. 2002, p. 11623 11636 Vol. 76, No. 22 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.22.11623 11636.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Escape
More informationComparison of Human Immunodeficiency Virus Antigens as Stimulants for Lymphocyte Proliferation Assays
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, May 2002, p. 525 529 Vol. 9, No. 3 1071-412X/02/$04.00 0 DOI: 10.1128/CDLI.9.3.525 529.2002 Copyright 2002, American Society for Microbiology. All Rights
More informationViral CTL Escape Mutants Are Generated in Lymph Nodes and Subsequently Become Fixed in Plasma and Rectal Mucosa during Acute SIV Infection of Macaques
Viral CTL Escape Mutants Are Generated in Lymph Nodes and Subsequently Become Fixed in Plasma and Rectal Mucosa during Acute SIV Infection of Macaques Thomas Howerton Vanderford, Emory University Chelsea
More informationSimian-Human Immunodeficiency Infection Is the Course Set in the Acute Phase?
Simian-Human Immunodeficiency Infection Is the Course Set in the Acute Phase? Janka Petravic, Miles P. Davenport* Complex Systems in Biology Group, Centre for Vascular Research, University of New South
More informationNANCY A WILSON SCHLEI Curriculum Vitae
NANCY A WILSON SCHLEI Curriculum Vitae Address: N64W28480 Meadowlark Ln Hartland, WI 53029 (262) 436-9577 Wisconsin National Primate Research Center AIDS Vaccine Research Laboratory 555 Science Drive.
More informationReceived 19 March 2003/Accepted 28 May 2003
JOURNAL OF VIROLOGY, Aug. 2003, p. 8729 8735 Vol. 77, No. 16 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.16.8729 8735.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Plasmid
More informationHeterologous Envelope Immunogens Contribute to AIDS Vaccine Protection in Rhesus Monkeys
JOURNAL OF VIROLOGY, July 2004, p. 7490 7497 Vol. 78, No. 14 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.14.7490 7497.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Heterologous
More informationReceived 17 April 2003/Accepted 28 June 2003
JOURNAL OF VIROLOGY, Oct. 2003, p. 10348 10356 Vol. 77, No. 19 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.19.10348 10356.2003 Cellular Immunity Elicited by Human Immunodeficiency Virus Type 1/ Simian Immunodeficiency
More informationImaging B Cell Follicles to Investigate HIV/SIV Persistence. Elizabeth Connick, M.D. University of Arizona May 8, 2017
Imaging B Cell ollicles to Investigate HIV/SIV Persistence Elizabeth Connick, M.D. University of Arizona May 8, 2017 Most HIV Replication Occurs In Secondary Lymphoid Tissues Tenner-Racz K et al. Am J
More informationModulation of DNA Vaccine-Elicited CD8 T-Lymphocyte Epitope Immunodominance Hierarchies
JOURNAL OF VIROLOGY, Dec. 2006, p. 11991 11997 Vol. 80, No. 24 0022-538X/06/$08.00 0 doi:10.1128/jvi.01348-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Modulation of DNA Vaccine-Elicited
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationIntroduction. University of Melbourne, Parkville, Vic., Australia, 2 Department of Pathology and Laboratory
J Med Primatol 2005: 34: 282 293 The pigtail macaque MHC class I allele Mane- A*10 presents an immundominant SIV Gag epitope: identification, tetramer development and implications of immune escape and
More informationReceived 26 September 2003/Accepted 22 December 2003
JOURNAL OF VIROLOGY, Apr. 2004, p. 3930 3940 Vol. 78, No. 8 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.8.3930 3940.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Highly Effective
More informationThe Role of B Cell Follicles in HIV Replication and Persistence
The Role of B Cell ollicles in HIV Replication and Persistence Elizabeth Connick, M.D. Professor of Medicine Chief, Division of Infectious Diseases University of Arizona July 17, 2016 IAS 2016 Towards
More informationVirology 391 (2009) Contents lists available at ScienceDirect. Virology. journal homepage:
Virology 391 (2009) 130 139 Contents lists available at ScienceDirect Virology journal homepage: www.elsevier.com/locate/yviro Nef-mediated MHC class I down-regulation unmasks clonal differences in virus
More informationHow Many Human Immunodeficiency Virus Type 1-Infected Target Cells Can a Cytotoxic T-Lymphocyte Kill?
JOURNAL OF VIROLOGY, Nov. 2005, p. 13579 13586 Vol. 79, No. 21 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.21.13579 13586.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. How Many
More informationReceived 17 March 2003/Accepted 16 July 2003
JOURNAL OF VIROLOGY, Nov. 2003, p. 11563 11577 Vol. 77, No. 21 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.21.11563 11577.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Multigene
More informationImmunological transitions in response to antigenic mutation during viral infection
International Immunology, Vol. 12, No. 10, pp. 1371 1380 2000 The Japanese Society for Immunology Immunological transitions in response to antigenic mutation during viral infection L. M. Wahl 2, B. Bittner
More informationEfficacy of DNA and Fowlpox Virus Priming/Boosting Vaccines for Simian/Human Immunodeficiency Virus
JOURNAL OF VIROLOGY, Dec. 2004, p. 13819 13828 Vol. 78, No. 24 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.24.13819 13828.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Efficacy
More informationHIV-1 infection is characterized by an early peak of viremia
The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals Marylyn M. Addo*, Marcus Altfeld*, Eric S. Rosenberg*, Robert L. Eldridge*,
More informationReceived 31 March 2011/Accepted 19 July 2011
JOURNAL OF VIROLOGY, Oct. 2011, p. 10518 10528 Vol. 85, No. 20 0022-538X/11/$12.00 doi:10.1128/jvi.00655-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Fitness Costs and Diversity
More informationReceived 22 April 2009/Accepted 19 June 2009
JOURNAL OF VIROLOGY, Sept. 2009, p. 9584 9590 Vol. 83, No. 18 0022-538X/09/$08.00 0 doi:10.1128/jvi.00821-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Protective Efficacy
More informationHLA-Associated Viral Mutations Are Common in Human Immunodeficiency Virus Type 1 Elite Controllers
JOURNAL OF VIROLOGY, Apr. 2009, p. 3407 3412 Vol. 83, No. 7 0022-538X/09/$08.00 0 doi:10.1128/jvi.02459-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. HLA-Associated Viral Mutations
More informationCD8 memory, immunodominance, and antigenic escape
2704 D. Wodarz and M. A. Nowak Eur. J. Immunol. 2000. 30: 2704 2712 CD8 memory, immunodominance, and antigenic escape Dominik Wodarz and Martin A. Nowak 1 Institute for Advanced Study, Princeton, USA Previous
More informationPerspectives of AIDS Vaccine Development: T Cell-based Vaccine
Perspectives of AIDS Vaccine Development: T Cell-based Vaccine Young Chul Sung National Research Lab., Department of Life Science, Pohang University of Science and Technology, Pohang, Korea ABSTRACT Estimated
More informationAND BRUCE D. WALKER 1
JOURNAL OF VIROLOGY, Feb 2001, p. 1339 1347 Vol. 75, No. 3 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.3.1339 1347.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Rapid Definition
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More informationFully Differentiated HIV-1 Specific CD8+ T Effector Cells are More Frequently Detectable in Controlled than in Progressive HIV-1 Infection
Fully Differentiated HIV-1 Specific CD8+ T Effector Cells are More Frequently Detectable in Controlled than in Progressive HIV-1 Infection The Harvard community has made this article openly available.
More informationOn an individual level. Time since infection. NEJM, April HIV-1 evolution in response to immune selection pressures
HIV-1 evolution in response to immune selection pressures BISC 441 guest lecture Zabrina Brumme, Ph.D. Assistant Professor, Faculty of Health Sciences Simon Fraser University http://www3.niaid.nih.gov/topics/hivaids/understanding/biology/structure.htm
More informationAbundance of Early Functional HIV-Specific CD8 + T Cells Does Not Predict AIDS-Free Survival Time
Abundance of Early Functional HIV-Specific CD8 + T Cells Does Not Predict AIDS-Free Survival Time Ingrid M. M. Schellens 1, José A. M. Borghans 1,2, Christine A. Jansen 3, Iris M. De Cuyper 3, Ronald B.
More informationVirus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef DAVID T. EVANS 1, DAVID H. O CONNOR 1, PEICHENG JING 1, JOHN L. DZURIS 2, JOHN
More informationMINI REVIEW. Dynamic interplay between viral adaptation and immune recognition during HIV-1 infection. Protein & Cell
Protein Cell 2010, 1(6): 514 519 DOI 10.1007/s13238-010-0068-0 MINI REVIEW Dynamic interplay between viral adaptation and immune recognition during HIV-1 infection Chihiro Motozono, Philip Mwimanzi, Takamasa
More informationTreatment with IL-7 Prevents the Decline of Circulating CD4 + T Cells during the Acute Phase of SIV Infection in Rhesus Macaques
SUPPORTING INFORMATION FOR: Treatment with IL-7 Prevents the Decline of Circulating CD4 + T Cells during the Acute Phase of SIV Infection in Rhesus Macaques Lia Vassena, 1,2 Huiyi Miao, 1 Raffaello Cimbro,
More informationCD8 T cells are essential for the control of human immunodeficiency
Expansion of Simian Immunodeficiency Virus (SIV)-Specific CD8 T Cell Lines from SIV-Naive Mauritian Cynomolgus Macaques for Adoptive Transfer Mariel S. Mohns, a Justin M. Greene, a Brian T. Cain, a Ngoc
More informationReceived 17 November 2003/Accepted 2 February 2004
JOURNAL OF VIROLOGY, July 2004, p. 7069 7078 Vol. 78, No. 13 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.13.7069 7078.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Selection,
More informationDoes Cytolysis by CD8 + T Cells Drive Immune Escape in HIV Infection?
The Journal of Immunology Does Cytolysis by CD8 + T Cells Drive Immune Escape in HIV Infection? Mehala Balamurali,* Janka Petravic,* Liyen Loh, Sheilajen Alcantara, Stephen J. Kent, and Miles P. Davenport*
More informationReceived 22 April 2002/Accepted 28 June 2002
JOURNAL OF VIROLOGY, Oct. 2002, p. 10147 10154 Vol. 76, No. 20 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.20.10147 10154.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Slowly
More informationNIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2009 July 1.
NIH Public Access Author Manuscript Published in final edited form as: Nature. 2009 January 1; 457(7225): 87 91. doi:10.1038/nature07469. Immune Control of an SIV Challenge by a T Cell-Based Vaccine in
More informationHuman Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8 -T-Cell Responses for Groups of HIV-1-Infected Individuals with Different HLA-B*35 Genotypes
JOURNAL OF VIROLOGY, Dec. 2002, p. 12603 12610 Vol. 76, No. 24 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.24.12603 12610.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Human
More informationGlobal Dysfunction of CD4 T-Lymphocyte Cytokine Expression in Simian-Human Immunodeficiency Virus/SIV-Infected Monkeys Is Prevented by Vaccination
JOURNAL OF VIROLOGY, Apr. 2003, p. 4695 4702 Vol. 77, No. 8 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.8.4695 4702.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Global Dysfunction
More informationUpdated information and services can be found at:
REFERENCES CONTENT ALERTS Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins John R.
More informationRecognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression
This information is current as of June 8, 2018. References Subscription Permissions Email Alerts Gag-Specific CD8 + T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein
More informationCD40L-Adjuvanted DNA/MVA SIV Vaccine Enhances Protection. Against Neutralization Resistant Mucosal SIV Infection
JVI Accepted Manuscript Posted Online 4 February 2015 J. Virol. doi:10.1128/jvi.03527-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 CD40L-Adjuvanted DNA/MVA SIV Vaccine
More informationMutational Escape in HIV-1 CTL Epitopes Leads to Increased Binding to Inhibitory Myelomonocytic MHC Class I Receptors
Mutational Escape in HIV-1 CTL Epitopes Leads to Increased Binding to Inhibitory Myelomonocytic MHC Class I Receptors The MIT Faculty has made this article openly available. Please share how this access
More informationReceived 18 January 2005/Accepted 18 April 2005
JOURNAL OF VIROLOGY, July 2005, p. 8828 8834 Vol. 79, No. 14 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.14.8828 8834.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. A Human T-Cell
More informationDesign and tests of an HIV vaccine
Design and tests of an HIV vaccine Andrew McMichael, Matilu Mwau and Tomas Hanke MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK Correspondence
More informationProtection afforded by live attenuated SIV is associated with rapid killing kinetics of CTLs
J Med Primatol doi:10.1111/j.1600-0684.2008.00326.x ORIGINAL ARTICLE Protection afforded by live attenuated SIV is associated with rapid killing kinetics of CTLs Erik Rollman, Rosemarie D. Mason, Jie Lin,
More information/JVI Updated information and services can be found at:
REFERENCES CONTENT ALERTS Critical Role for Env as well as Gag-Pol in Control of a Simian-Human Immunodeficiency Virus 89.6P Challenge by a DNA Prime/Recombinant Modified Vaccinia Virus Ankara Vaccine
More informationEquine infectious anaemia virus proteins with epitopes most frequently recognized by cytotoxic T lymphocytes from infected horses
Journal of General Virology (2000), 81, 2735 2739. Printed in Great Britain... SHORT COMMUNICATION Equine infectious anaemia virus proteins with epitopes most frequently recognized by cytotoxic T lymphocytes
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
More informationMechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI
Mechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI Problems Virus escape from immune recognition Antagonism of T cell responses Peptide-MHC-TCR interaction T cell antagonism Variants of
More informationImmunoprophylaxis against AIDS in macaques with a lentiviral DNA vaccine
Virology 351 (2006) 444 454 www.elsevier.com/locate/yviro Immunoprophylaxis against AIDS in macaques with a lentiviral DNA vaccine ZhenQian Liu a, Dinesh K. Singh a,1, Darlene Sheffer a, Marilyn S. Smith
More informationDepartment of Surgery, Duke University, Durham, North Carolina; and 7 Southern Research Institute, Frederick, Maryland
MAJOR ARTICLE Highly Attenuated Rabies Virus Based Vaccine Vectors Expressing Simian-Human Immunodeficiency Virus 89.6P Env and Simian Immunodeficiency Virus mac239 Gag Are Safe in Rhesus Macaques and
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Adaptive Immunity Innate immunity: (Antigen - nonspecific) defense
More informationVirus-specific CD8 cytotoxic T lymphocytes (CTLs) are major
Association of Major Histocompatibility Complex Class I Haplotypes with Disease Progression after Simian Immunodeficiency Virus Challenge in Burmese Rhesus Macaques Takushi Nomura, a,b Hiroyuki Yamamoto,
More informationDetailed Analysis of the CD8 T-Cell Response following Adenovirus Vaccination
JOURNAL OF VIROLOGY, Dec. 2003, p. 13407 13411 Vol. 77, No. 24 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.24.13407 13411.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Detailed
More informationCD8 down-regulation and functional impairment of SIV-specific cytotoxic T lymphocytes in lymphoid and mucosal tissues during SIV infection
Article CD8 down-regulation and functional impairment of SIV-specific cytotoxic T lymphocytes in lymphoid and mucosal tissues during SIV infection Huanbin Xu, Xiaolei Wang, Andrew A. Lackner, and Ronald
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationReceived 29 August 2002/Accepted 3 December 2002
JOURNAL OF VIROLOGY, Mar. 2003, p. 3099 3118 Vol. 77, No. 5 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.5.3099 3118.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Simian-Human
More informationMassive infection and loss of memory CD4 + T cells in multiple tissues during acute SIV infection
Massive infection and loss of memory CD4 + T cells in multiple tissues during acute SIV infection Joseph J. Mattapallil 1, Daniel C. Douek 2, Brenna Hill 2, Yoshiaki Nishimura 3, Malcolm Martin 3 & Mario
More informationReceived 10 November 2010/Accepted 13 January 2011
JOURNAL OF VIROLOGY, Apr. 2011, p. 3250 3261 Vol. 85, No. 7 0022-538X/11/$12.00 doi:10.1128/jvi.02355-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Transcriptionally Abundant
More informationStrategies for an HIV vaccine
Strategies for an HIV vaccine Norman L. Letvin J Clin Invest. 2002;110(1):15-27. https://doi.org/10.1172/jci15985. Perspective The development of an HIV vaccine poses an unprecedented challenge to the
More informationReceived 4 December 2001/Accepted 29 April 2002
JOURNAL OF VIROLOGY, Aug. 2002, p. 8433 8445 Vol. 76, No. 16 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.16.8433 8445.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. The Relationship
More informationReceived 25 September 2009/Accepted 5 January 2010
JOURNAL OF VIROLOGY, Apr. 2010, p. 3362 3372 Vol. 84, No. 7 0022-538X/10/$12.00 doi:10.1128/jvi.02028-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Extralymphoid CD8 T Cells
More informationAntiviral therapy for HIV-infected patients has greatly improved
Specific therapy regimes could lead to long-term immunological control of HIV Dominik Wodarz* and Martin A. Nowak Institute for Advanced Study, Olden Lane, Princeton, NJ 08540 Communicated by Phillip A.
More informationPotential cross reactions between HIV 1 specific T cells and the microbiome. Andrew McMichael Suzanne Campion
Potential cross reactions between HIV 1 specific T cells and the microbiome Andrew McMichael Suzanne Campion Role of the Microbiome? T cell (and B cell) immune responses to HIV and Vaccines are influenced
More informationSUPPLEMENTARY INFORMATION
` SUPPLEMENTAL FIGURES doi:10.1038/nature10003 Supplemental Figure 1: RhCMV/SIV vectors establish and indefinitely maintain high frequency SIV-specific T cell responses in diverse tissues: The figure shows
More informationT-Pharmacytes for the Targeted Eradication of HIV Reservoirs
T-Pharmacytes for the Targeted Eradication of HIV Reservoirs Walker Lab Rachel O Connor Alicja Trocha Dan Karel Irvine Lab Stefanie Mueller Humanized Mouse Core Vlad Vrbanac Andy Tager Todd Allen Darrell
More informationRapid Reversion of Sequence Polymorphisms Dominates Early Human Immunodeficiency Virus Type 1 Evolution
REFERENCES CONTENT ALERTS Rapid Reversion of Sequence Polymorphisms Dominates Early Human Immunodeficiency Virus Type 1 Evolution Bin Li, Adrianne D. Gladden, Marcus Altfeld, John M. Kaldor, David A. Cooper,
More informationHIV Anti-HIV Neutralizing Antibodies
,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious
More informationControl of Human Immunodeficiency Virus Type 1 Is Associated with HLA-B*13 and Targeting of Multiple Gag-Specific CD8 T-Cell Epitopes
JOURNAL OF VIROLOGY, Apr. 2007, p. 3667 3672 Vol. 81, No. 7 0022-538X/07/$08.00 0 doi:10.1128/jvi.02689-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Control of Human Immunodeficiency
More informationComparison of the efficacy of early versus late viral proteins in vaccination against SIV
Vaccine 20 (2002) 2921 2927 Comparison of the efficacy of early versus late viral proteins in vaccination against SIV Koert J. Stittelaar a, Rob A. Gruters a,b, Martin Schutten a, Carel A. van Baalen a,
More informationJOURNAL OF VIROLOGY, Mar. 1999, p Vol. 73, No. 3. Copyright 1999, American Society for Microbiology. All Rights Reserved.
JOURNAL OF VIROLOGY, Mar. 1999, p. 1853 1859 Vol. 73, No. 3 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Acute Effects of Pathogenic Simian-Human Immunodeficiency
More informationThe global spread of the human immunodeficiency virus (HIV)
Immunological and Virological Analyses of Rhesus Macaques Immunized with Chimpanzee Adenoviruses Expressing the Simian Immunodeficiency Virus Gag/Tat Fusion Protein and Challenged Intrarectally with Repeated
More informationUpdated information and services can be found at:
REFERENCES CONTENT ALERTS Comprehensive Immunological Evaluation Reveals Surprisingly Few Differences between Elite Controller and Progressor Mamu-B*17-Positive Simian Immunodeficiency Virus-Infected Rhesus
More informationIdentification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing
More informationNOTES. Michael D. George,* David Verhoeven, Sumathi Sankaran, Tiffany Glavan, Elizabeth Reay, and Satya Dandekar
CLINICAL AND VACCINE IMMUNOLOGY, Feb. 2009, p. 277 281 Vol. 16, No. 2 1556-6811/09/$08.00 0 doi:10.1128/cvi.00265-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. NOTES Heightened
More information